Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

WARRIOR: No Clear Answers on How to Best Treat INOCA

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

April 06, 2024

STREAM-2: Half-Dose Tenecteplase Safe, Effective in Older STEMI Patients

News Conference News ACC 2023

STREAM-2: Half-Dose Tenecteplase Safe, Effective in Older STEMI Patients

March 10, 2023

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

News Conference News ACC 2023

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

March 09, 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

News Conference News ACC 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Michael O'Riordan

March 09, 2023

Wrist-Worn Sensor May Help Detect Elevated Troponin in ACS

News Conference News ACC 2023

Wrist-Worn Sensor May Help Detect Elevated Troponin in ACS

March 06, 2023

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

News Conference News ACC 2023

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

March 06, 2023

BIO|GUARD-MI: Post-MI Arrhythmia Monitoring Falls Short

News Conference News ACC 2022

BIO|GUARD-MI: Post-MI Arrhythmia Monitoring Falls Short

April 11, 2022

Emergent CABG in Acute MI: Survival Better Despite Increasingly Risky Patients

News Conference News ACC 2021

Emergent CABG in Acute MI: Survival Better Despite Increasingly Risky Patients

May 15, 2021

For Younger MI Survivors, Stress Boosts Adverse Outcomes

News Conference News ACC 2021

For Younger MI Survivors, Stress Boosts Adverse Outcomes

May 13, 2021

Initiation of Angiotensin-Neprilysin Inhibition after Acute Decompensated Heart Failure: Results of the Open-Label Extension of the PIONEER-HF Trial

Presentation ACC 2019

Initiation of Angiotensin-Neprilysin Inhibition after Acute Decompensated Heart Failure: Results of the Open-Label Extension of the PIONEER-HF Trial

Presenter: Adam D. DeVore

March 17, 2019

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

News Conference News ACC 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Michael O'Riordan

March 11, 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

March 05, 2018

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

News Conference News ACC 2018

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

Michael O'Riordan

March 01, 2018

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

News Conference News ACC 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

March 18, 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.